Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported a revenue of $425.9 million for its Design IP segment in Q3 2025, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of Q3 2025 financial results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6]. - The decline was attributed to customers requiring more customization for IP components, which negatively impacted the economics of the Design IP business [5][6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [4]. Allegations and Stock Impact - The lawsuit alleges that Stride inflated enrollment numbers by retaining "ghost students," ignored compliance requirements, and had a poor customer experience leading to higher withdrawal rates and lower conversion rates [4]. - On September 14, 2025, a report of fraud and deceptive practices caused Stride's stock to drop by $18.60 per share, over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, more than 54%, from $153.53 to $70.05 [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [3]. Investor Information - Investors are encouraged to seek additional information regarding their legal options and can submit their information to the law firm handling the case [2][7].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018 [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations of Fraud - The complaint alleges that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, claiming sustainable customer demand when, in fact, sales were driven by inventory loading by channel partners [5]. - The company stated on May 20, 2025, that it was experiencing "normal stock levels" and expected performance, which was later contradicted by actual sales data [5]. Group 4: Stock Performance Impact - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, revealing that customers were destocking to return to normal inventory levels [6]. - Following this announcement, the stock price plummeted by $9.79 per share, a decrease of over 34%, from $28.43 to $18.64 per share within a day [6].

Core Viewpoint - Ardent Health, Inc. is under investigation for potential securities fraud due to improper accounting practices related to accounts receivable and professional liability reserves [3]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in revenue for Q3 2025 after conducting "hindsight evaluations of historical collection trends" [4]. - The company also increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [4]. - Following these disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [4]. Legal Context - Bleichmar Fonti & Auld LLP is leading the investigation into Ardent Health for potential violations of federal securities laws [1]. - Investors are encouraged to seek additional information and may have legal options available [2][5].

LRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Stride, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Share SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Stride, Inc. (NYSE: LRN) securities between October 22, 2024 and October 28, 2025, both dates inclusive (the "Class Period†), have until January 12, 2026 to seek appointment as lead plaintiff of the Stride class action laws ...

Core Viewpoint - The Schall Law Firm is investigating claims against Netflix, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements or failed to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation aims to determine if Netflix issued false and/or misleading statements or failed to disclose relevant information to investors [2]. - Investors who have suffered losses are encouraged to participate in the investigation [2]. Group 2: Contact Information - Investors can contact Brian Schall of the Schall Law Firm for a free discussion regarding their rights [3]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation [3].

Accessibility StatementSkip Navigation NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:     Laurence Rosen, Esq.    Phillip Kim, Esq.    The Rosen Law Firm, P.A.    275 Madison Avenue, 40 Floor    New York, NY 10016    Tel: (212) 686-1060    Toll Free: (866) 767-3653    Fax: (212) 202-3827     [email protected]    www.rosenlegal.com Why: Rosen Law Firm, a global investor rights law f ...

Core Points - A class action securities lawsuit has been filed against Avantor, Inc. to recover losses for shareholders affected by alleged securities fraud between March 5, 2024, and October 28, 2025 [2] - The complaint alleges that Avantor's competitive positioning was misrepresented, indicating that the company was facing negative impacts from increased competition, which rendered the defendants' statements about the company's business and prospects materially false and misleading [3] Next Steps - Shareholders who suffered losses in Avantor, Inc. stock during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders, having ranked in the Top 50 Report for seven consecutive years [5]

Core Insights - Tvardi Therapeutics, Inc. is under investigation for possible violations of federal securities laws following disappointing results from its Phase 2 REVERT study of TTI-101, a STAT3 inhibitor for idiopathic pulmonary fibrosis (IPF) [1][2] - The Phase 2 study did not meet its goals, with no statistically significant differences observed between the treatment and placebo groups, and a high discontinuation rate of over 56% in treatment arms compared to 10.3% in the placebo group [2] - Following the announcement of the study results, Tvardi's stock price dropped significantly by $34.91, closing at $6.69 per share [3] Company Overview - Tvardi Therapeutics is focused on developing treatments for serious diseases, specifically targeting idiopathic pulmonary fibrosis with its drug TTI-101 [2] - The company has faced challenges in its clinical trials, as indicated by the recent Phase 2 study results [2] Legal Context - Levi & Korsinsky LLP, a recognized securities litigation firm, has initiated an investigation into Tvardi Therapeutics, indicating potential legal ramifications for the company [1][4] - The firm has a strong track record in securities litigation, having secured significant settlements for shareholders in the past [4]

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws, with claims that the company misrepresented its business prospects and financial performance during its IPO and subsequent reporting period [1][3][4]. Company Overview - Firefly Aerospace operates in the space and defense technology sector, providing mission solutions for national security, government, and commercial customers [2]. IPO Details - The company conducted its initial public offering (IPO) on August 7, 2025, issuing approximately 19.3 million shares at an offering price of $45.00 per share [2]. Allegations of Misrepresentation - The lawsuit alleges that Firefly Aerospace overstated demand and growth prospects for its Spacecraft Solutions offerings, as well as the operational readiness and commercial viability of its Alpha rocket program [3]. Financial Performance - In its first earnings report as a public company on September 22, 2025, Firefly Aerospace reported a loss of $80.3 million for Q2 2025, compared to a loss of $58.7 million in Q2 2024. Revenue was reported at $15.55 million, below analyst estimates of $17.25 million, and down 26.2% year-over-year [4]. - The Spacecraft Solutions business segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [4]. Stock Price Impact - Following the earnings report, Firefly Aerospace's stock price fell more than 15%. Additionally, on September 29, 2025, the company disclosed an issue with its Alpha Flight 7 rocket, leading to a further decline of over 20% in its stock price [4][5].